



Inflammatory Cytokines as New Therapeutic Targets

Guest Editors:

Prof. Dr. Jae Seung Kang

Department of Anatomy and Cell
Biology, Institute of Allergy and
Clinical Immunology, Seoul
National University College of
Medicine, Seoul 03080, Republic
of Korea

Prof. Dr. Yejin Kim

Laboratory of Vitamin C and
Antioxidant Immunology,
Department of Anatomy and Cell
Biology, Seoul National
University College of Medicine,
Seoul 03080, Republic of Korea

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

It is generally known that inflammatory responses are accompanied by the regulation of autoimmune diseases, infectious diseases, and cancers by the immune system. In this process, excessive production of inflammatory cytokine by inflammatory immune cells that mediate inflammatory reactions is known to make the disease get worse. Therefore, research regarding immunomodulating molecules, including monoclonal antibodies and small chemical compounds, is needed to regulate the production and function of inflammatory cytokines in this regard.

In this Special Issue, we will deal with research on the regulation of inflammatory immune cells and various kinds of inflammatory cytokines produced by these cells. Reviews and original papers discussing these points are welcome.

Prof. Dr. Jae Seung Kang

Prof. Dr. Yejin Kim

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com